HR Execs on the Move

Wellteq

www.wellteq.co

 
Wellteq is creating the future of precision wellness through a digital wellbeing ecosystem taking users from point of prevention through to point of care. Delivered into the corporate health and insurance sector to drive user engagement through a personalised wellness journey. wellteq uses a range of data types from wearable devices, sensors, biomarkers and user-generated data that, in combination with machine learning and artificial intelligence enables individual-level insights into Stress, Fatigue, Sleep Quality, Cognitive Function and Activity levels. Behavioural science and content targeting use biometric and behavioural analytics to deliver personalised wellness insights and practical recommendations to build engagement, agency ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.wellteq.co
  • 580 Hornby Street Suite 880
    Vancouver, BC USA V6C 3B6
  • Phone: 647.256.1986

Executives

Name Title Contact Details
Olly Bridge
Chief Growth Officer Profile

Similar Companies

Asian Pacific Cmnty Counseling

Asian Pacific Cmnty Counseling is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mercy Health System

Mercy Health System is the largest Catholic healthcare system serving the Delaware Valley and is a member of Catholic Health East, a multi-institutional, Catholic health system co-sponsored by 13 religious congregations and Hope Ministries.

Endocare

Endocare is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Endocare is based in Irvine, CA. You can find more information on Endocare at www.endocare.com

HyGreen

HyGreen is a Gainesville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.